Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") of a class action securities lawsuit.

Rising costs and complex care make diabetes a daily challenge. Local patient and pharmacy expert share strategies, struggles, ...

Levi & Korsinsky, LLP notifies investors in DexCom, Inc. (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of DexCom investors who ...

Levi & Korsinsky, LLP notifies investors in DexCom, Inc. (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of DexCom investors who ...

Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plai ...

Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom, Inc." or the "Company") (NASDAQ: DXCM) of a ...

If you invested in DexCom, you are encouraged to obtain additional information by visiting: Investors have until December 26, 2025, to ask the Court to be appointed to lead the case. The complaint ...

Dexcom has issued a Class I recall for its G6 Android app due to crashes that could cause users to miss critical glucose ...

The global Blood Glucose Monitoring System Market, valued at US$15.16 billion in 2024, stood at US$16.46 billion in 2025 and ...

If you have suffered a loss on your DexCom, Inc. ("DexCom" or the "Company") (NASDAQ:DCXM) investment, contact Thomas W. Elrod of Kirby McInerney LLP by email at [email protected], or fill out ...

DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.